Hani Faidah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hani Faidah has a total of 125 co-authors. Here are the top co-authors by number of shared publications:
- Farkad Bantun
Department of Microbiology and Parasitology, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia
8 shared publications - Abdul Haseeb
Department of Clinical Pharmacy, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia
7 shared publications - Mahmoud Essam Elrggal
College of Medicine, Al Qunfudah Umm Al-Qura University, Al Qunfudhah 28821, Saudi Arabia
6 shared publications - Naif A. Jalal
Department of Microbiology and Parasitology, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia
6 shared publications - Ahmad Jamal Mahrous
Department of Pharmaceutical Practices, College of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia
5 shared publications - Ayman Khalid Johargy
Department of Microbiology and Parasitology, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia
5 shared publications
Latest Publications
- Open Access
- 3 September 2025
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 18 (11) , 102951
Respiratory and gastrointestinal infections among Hajj pilgrims during the 2012–2025 seasons: A systematic review
- 3 September 2025
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 18 (11) , 102951
Open AccessRespiratory and gastrointestinal infections among Hajj pilgrims during the 2012–2025 seasons: A systematic review
- Open Access
- 16 June 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (6) , 879
Probiotics and Cancer: Mechanistic Insights and Organ-Specific Impact
Probiotics have been revealed in various studies to modulate the gut microbiome and have a substantial impact on cancers, comprising oesophageal, lung, liver, and colorectal cancer. These properties are endorsed by a diverse mechanism, including the modulation of the gut microbiome; preventing the metabolism of carcinogenic substances; exertion of anti-inflammatory action, immunopotentiator properties, and antioxidant activities; prevention of tumour growth; and decreasing the adverse effects of chemotherapy. There are promising perspectives regarding the new and developing field of probiotic research in relation to cancer treatment. This review demonstrates the recent findings of probiotics efficacy in cancer prevention and treatment and organ-specific impact along with protection from chemotherapy-induced side effects. The present evidence specifies that strategic probiotics application may be an effective complementary approach for the management of numerous kinds of cancer; still, additional studies and clinical trials are required to comprehend the relationships between cancer and probiotics.
- 16 June 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (6) , 879
Open AccessProbiotics and Cancer: Mechanistic Insights and Organ-Specific Impact
Probiotics have been revealed in various studies to modulate the gut microbiome and have a substantial impact on cancers, comprising oesophageal, lung, liver, and colorectal cancer. These properties are endorsed by a diverse mechanism, including the modulation of the gut microbiome; preventing the metabolism of carcinogenic substances; exertion of anti-inflammatory action, immunopotentiator properties, and antioxidant activities; prevention of tumour growth; and decreasing the adverse effects of chemotherapy. There are promising perspectives regarding the new and developing field of probiotic research in relation to cancer treatment. This review demonstrates the recent findings of probiotics efficacy in cancer prevention and treatment and organ-specific impact along with protection from chemotherapy-induced side effects. The present evidence specifies that strategic probiotics application may be an effective complementary approach for the management of numerous kinds of cancer; still, additional studies and clinical trials are required to comprehend the relationships between cancer and probiotics.
- Open Access
- 7 March 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (3) , 274
Prevalence and Antibiogram Pattern of Acinetobacter baumannii from 2013 to 2023 in a Tertiary Care Hospital in the Western Region of Saudi Arabia
Acinetobacter baumannii is pathogen of global concern. It causes infection, especially among immunocompromised individuals in intensive care units, due to its ability to survive for long periods on hard surfaces and under a wide range of environmental conditions and become resistant to almost all the available antibiotics used in clinical practice. Objectives: This study aims to address the gap in A. baumannii surveillance in Saudi Arabia by tracking the prevalence, patterns, and trends of acquired A. baumannii resistance at a healthcare facility in the western part of Saudi Arabia over eleven years. Methods: The study was conducted in a tertiary care hospital in the western region of Saudi Arabia, from January 2013 to December 2023. Results: Our data indicated that A. baumannii infections were predominantly observed in inpatients admitted to the hospital (96%) compared to those treated as outpatients in the emergency clinic (4%). The mean of annual A. baumannii infections isolated from inpatients is 503.3, whereas the mean for outpatients is 21, indicating a statistically significant difference with a p-value of A. baumannii demonstrated a variable levels of resistance to the evaluated antibiotics. The lowest resistance rate was for colistin. Conclusions: In conclusion, the incidence patterns of A. baumannii isolates peaked in 2013, then declined, and have recently shown an increase, underscoring the necessity for proactive interventions to curtail its dissemination, notwithstanding initial decreases in infection rates and resistance.
- 7 March 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (3) , 274
Open AccessPrevalence and Antibiogram Pattern of Acinetobacter baumannii from 2013 to 2023 in a Tertiary Care Hospital in the Western Region of Saudi Arabia
Acinetobacter baumannii is pathogen of global concern. It causes infection, especially among immunocompromised individuals in intensive care units, due to its ability to survive for long periods on hard surfaces and under a wide range of environmental conditions and become resistant to almost all the available antibiotics used in clinical practice. Objectives: This study aims to address the gap in A. baumannii surveillance in Saudi Arabia by tracking the prevalence, patterns, and trends of acquired A. baumannii resistance at a healthcare facility in the western part of Saudi Arabia over eleven years. Methods: The study was conducted in a tertiary care hospital in the western region of Saudi Arabia, from January 2013 to December 2023. Results: Our data indicated that A. baumannii infections were predominantly observed in inpatients admitted to the hospital (96%) compared to those treated as outpatients in the emergency clinic (4%). The mean of annual A. baumannii infections isolated from inpatients is 503.3, whereas the mean for outpatients is 21, indicating a statistically significant difference with a p-value of A. baumannii demonstrated a variable levels of resistance to the evaluated antibiotics. The lowest resistance rate was for colistin. Conclusions: In conclusion, the incidence patterns of A. baumannii isolates peaked in 2013, then declined, and have recently shown an increase, underscoring the necessity for proactive interventions to curtail its dissemination, notwithstanding initial decreases in infection rates and resistance.
- 1 October 2024
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 30 (36) , 2829-2834
An Update on Colistin in Clinical Healthcare Unit in the Kingdom of Saudi Arabia: A Narrative Review
: Globally, gram-negative bacteria are a significant cause of morbidity. Multi-drug resistance bacteria are responsible for an increasing surge in infections that place a high cost on healthcare systems around the world. Recently, colistin, an antibiotic belonging to the polymyxin family, was reintroduced to combat multidrug- resistant gram-negative bacteria. Excessive and persistent use of colistin has led to the development and spread of colistin-resistant gram-negative bacteria throughout the globe. Healthcare units in various countries, including Saudi Arabia, are currently battling colistin-resistant gram-negative bacteria. Recently, colistin-resistant gram-negative bacteria have become a major health concern in Saudi Arabia. Hence, extensive epidemiological surveys and studies are required to understand the current status of the colistin antibiotic. Examining the knowledge currently available to the medical community on the molecular mechanism, clinical effectiveness, molecular epidemiology, and bacterial resistance to colistin in Saudi Arabia is the aim of this review.
- 1 October 2024
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 30 (36) , 2829-2834
An Update on Colistin in Clinical Healthcare Unit in the Kingdom of Saudi Arabia: A Narrative Review
: Globally, gram-negative bacteria are a significant cause of morbidity. Multi-drug resistance bacteria are responsible for an increasing surge in infections that place a high cost on healthcare systems around the world. Recently, colistin, an antibiotic belonging to the polymyxin family, was reintroduced to combat multidrug- resistant gram-negative bacteria. Excessive and persistent use of colistin has led to the development and spread of colistin-resistant gram-negative bacteria throughout the globe. Healthcare units in various countries, including Saudi Arabia, are currently battling colistin-resistant gram-negative bacteria. Recently, colistin-resistant gram-negative bacteria have become a major health concern in Saudi Arabia. Hence, extensive epidemiological surveys and studies are required to understand the current status of the colistin antibiotic. Examining the knowledge currently available to the medical community on the molecular mechanism, clinical effectiveness, molecular epidemiology, and bacterial resistance to colistin in Saudi Arabia is the aim of this review.
- Open Access
- 1 May 2024
- Published by Scientific Scholar in Journal of King Saud University – Science
- Vol. 36 (5)
A meta-analysis of cohort and pilot studies indicates association of mouthwash use and risk of hypertension in adults
The relationship between high blood pressure (hypertension) incidence and mouthwash use is a subject of ongoing research. Origin of this link may lie in mouthwash-mediated destruction of oral microflora, and consequently reduced nitric oxide (NO) bioavailability. In this study, we evaluated the association between mouthwash use and the risk of hypertension through statistical meta-analysis of published cohort and cross-sectional studies. The search strategy and selection of research articles was in accord with PRISMA guidelines, and under pre-defined set of inclusion criteria. Primary research studies focused on “association among use of mouthwash and risk of hypertension incidence” were searched on databases such as PubMed, EMBASE, MEDLINE, and Cochrane Library. MesH keywords such as “hypertension”, “mouthwash use”, “risk of HTN”, “HTN incidence”, “nitric oxide bioavailability”, and “cohort studies” were used. Out of 1650 studies, 9 met all the inclusion criteria and were finally selected. RevMan 5.3 software was employed for statistical analyses of data retrieved from these selected studies. About 6384 adults with mild hypertension symptoms were included in this meta-analysis from different cohort, pilot and cross-sectional studies. All participants’ ages ranged between 40 and 60 years with mild symptoms of hypertension. While high statistical heterogeneity was observed, our results indicate a significant association of antiseptic mouthwash use with the risk of developing hypertension. The findings reveal a slightly but significantly elevated risk of development of hypertension among regular antiseptic mouthwash users, in comparison to non-users. However, further studies are needed to confirm and establish this relationship further.
- 1 May 2024
- Published by Scientific Scholar in Journal of King Saud University – Science
- Vol. 36 (5)
Open AccessA meta-analysis of cohort and pilot studies indicates association of mouthwash use and risk of hypertension in adults
The relationship between high blood pressure (hypertension) incidence and mouthwash use is a subject of ongoing research. Origin of this link may lie in mouthwash-mediated destruction of oral microflora, and consequently reduced nitric oxide (NO) bioavailability. In this study, we evaluated the association between mouthwash use and the risk of hypertension through statistical meta-analysis of published cohort and cross-sectional studies. The search strategy and selection of research articles was in accord with PRISMA guidelines, and under pre-defined set of inclusion criteria. Primary research studies focused on “association among use of mouthwash and risk of hypertension incidence” were searched on databases such as PubMed, EMBASE, MEDLINE, and Cochrane Library. MesH keywords such as “hypertension”, “mouthwash use”, “risk of HTN”, “HTN incidence”, “nitric oxide bioavailability”, and “cohort studies” were used. Out of 1650 studies, 9 met all the inclusion criteria and were finally selected. RevMan 5.3 software was employed for statistical analyses of data retrieved from these selected studies. About 6384 adults with mild hypertension symptoms were included in this meta-analysis from different cohort, pilot and cross-sectional studies. All participants’ ages ranged between 40 and 60 years with mild symptoms of hypertension. While high statistical heterogeneity was observed, our results indicate a significant association of antiseptic mouthwash use with the risk of developing hypertension. The findings reveal a slightly but significantly elevated risk of development of hypertension among regular antiseptic mouthwash users, in comparison to non-users. However, further studies are needed to confirm and establish this relationship further.
- Open Access
- 22 April 2024
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 17 (6) , 1108-1116
Binding selectivity analysis of new delhi metallo-beta-lactamase-1 inhibitors using molecular dynamics simulations: Exploring possibilities for decoding antimicrobial drug resistance
- 22 April 2024
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 17 (6) , 1108-1116
Open AccessBinding selectivity analysis of new delhi metallo-beta-lactamase-1 inhibitors using molecular dynamics simulations: Exploring possibilities for decoding antimicrobial drug resistance
- Open Access
- 28 August 2023
- Published by MDPI AG in Antioxidants
- Vol. 12 (9) , 1679
Therapeutic Potential of Green-Engineered ZnO Nanoparticles on Rotenone-Exposed D. melanogaster (Oregon R+): Unveiling Ameliorated Biochemical, Cellular, and Behavioral Parameters
Nanotechnology holds significant ameliorative potential against neurodegenerative diseases, as it can protect the therapeutic substance and allow for its sustained release. In this study, the reducing and capping agents of Urtica dioica (UD), Matricaria chamomilla (MC), and Murraya koenigii (MK) extracts were used to synthesize bio-mediated zinc oxide nanoparticles (ZnO-NPs) against bacteria (Staphylococcus aureus and Escherichia coli) and against rotenone-induced toxicities in D. melanogaster for the first time. Their optical and structural properties were analyzed via FT-IR, DLS, XRD, EDS, SEM, UV–Vis, and zeta potential. The antioxidant and antimicrobial properties of the fabricated ZnO-NPs were evaluated employing cell-free models (DPPH and ABTS) and the well diffusion method, respectively. Rotenone (500 µM) was administered to Drosophila third instar larvae and freshly emerged flies for 24–120 h, either alone or in combination with plant extracts (UD, MC, an MK) and their biogenic ZnO-NPs. A comparative study on the protective effects of synthesized NPs was undertaken against rotenone-induced neurotoxic, cytotoxic, and behavioral alterations using an acetylcholinesterase inhibition assay, dye exclusion test, and locomotor parameters. The findings revealed that among the plant-derived ZnO-NPs, MK-ZnO NPs exhibit strong antimicrobial and antioxidant activities, followed by UD-ZnO NPs and MC-ZnO NPs. In this regard, ethno-nano medicinal therapeutic uses mimic similar effects in D. melanogaster by suppressing oxidative stress by restoring biochemical parameters (AchE and proteotoxicity activity) and lower cellular toxicity. These findings suggest that green-engineered ZnO-NPs have the potential to significantly enhance outcomes, with the promise of effective therapies for neurodegeneration, and could be used as a great alternative for clinical development.
- 28 August 2023
- Published by MDPI AG in Antioxidants
- Vol. 12 (9) , 1679
Open AccessTherapeutic Potential of Green-Engineered ZnO Nanoparticles on Rotenone-Exposed D. melanogaster (Oregon R+): Unveiling Ameliorated Biochemical, Cellular, and Behavioral Parameters
Nanotechnology holds significant ameliorative potential against neurodegenerative diseases, as it can protect the therapeutic substance and allow for its sustained release. In this study, the reducing and capping agents of Urtica dioica (UD), Matricaria chamomilla (MC), and Murraya koenigii (MK) extracts were used to synthesize bio-mediated zinc oxide nanoparticles (ZnO-NPs) against bacteria (Staphylococcus aureus and Escherichia coli) and against rotenone-induced toxicities in D. melanogaster for the first time. Their optical and structural properties were analyzed via FT-IR, DLS, XRD, EDS, SEM, UV–Vis, and zeta potential. The antioxidant and antimicrobial properties of the fabricated ZnO-NPs were evaluated employing cell-free models (DPPH and ABTS) and the well diffusion method, respectively. Rotenone (500 µM) was administered to Drosophila third instar larvae and freshly emerged flies for 24–120 h, either alone or in combination with plant extracts (UD, MC, an MK) and their biogenic ZnO-NPs. A comparative study on the protective effects of synthesized NPs was undertaken against rotenone-induced neurotoxic, cytotoxic, and behavioral alterations using an acetylcholinesterase inhibition assay, dye exclusion test, and locomotor parameters. The findings revealed that among the plant-derived ZnO-NPs, MK-ZnO NPs exhibit strong antimicrobial and antioxidant activities, followed by UD-ZnO NPs and MC-ZnO NPs. In this regard, ethno-nano medicinal therapeutic uses mimic similar effects in D. melanogaster by suppressing oxidative stress by restoring biochemical parameters (AchE and proteotoxicity activity) and lower cellular toxicity. These findings suggest that green-engineered ZnO-NPs have the potential to significantly enhance outcomes, with the promise of effective therapies for neurodegeneration, and could be used as a great alternative for clinical development.
- Open Access
- 8 August 2023
- Published by MDPI AG in Antibiotics
- Vol. 12 (8) , 1299
Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
Hajj pilgrimage is a large mass gathering global event that may facilitate the spread and emergence of various infectious diseases as well as antimicrobial resistance (AMR) in a local and global scenario. Planning and preparing for these public health issues is a challenging and complex process for the Kingdom of Saudi Arabia (KSA) health authorities. Despite multiple efforts for the prevention and treatment of infectious diseases through longtime funding in education and medical care, the prevalence of infectious disease is still high among Hajj pilgrims. The commonly observed infectious diseases during Hajj include respiratory tract infections (influenza and pneumonia), urinary tract infections and skin infections that may necessitate the use of antimicrobials. Beta-lactams are used as a first-line treatment for hospital acquired infections as well as community acquired infections due to their broad-spectrum activity. However, most of the bacterial isolates such as Staphylococcus spp., Pseudomonas spp. and E. coli are resistant to beta-lactams. Irrational use of antimicrobials, lack of infection prevention practices and suboptimal healthcare access further exacerbate the risk of spreading AMR among Hajj pilgrims. Enhanced collaboration between countries, sharing of best practices and international cooperation are crucial in addressing AMR threats among pilgrims. Consequently, robust surveillance systems for early detection and monitoring of AMR, collaboration with national as well as international healthcare agencies, effective infection prevention and control measures, public awareness and rational use of antimicrobials via antimicrobial stewardship programs are required to mitigate the risk of AMR and ensure the health and well-being of pilgrims during Hajj.
- 8 August 2023
- Published by MDPI AG in Antibiotics
- Vol. 12 (8) , 1299
Open AccessThreat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
Hajj pilgrimage is a large mass gathering global event that may facilitate the spread and emergence of various infectious diseases as well as antimicrobial resistance (AMR) in a local and global scenario. Planning and preparing for these public health issues is a challenging and complex process for the Kingdom of Saudi Arabia (KSA) health authorities. Despite multiple efforts for the prevention and treatment of infectious diseases through longtime funding in education and medical care, the prevalence of infectious disease is still high among Hajj pilgrims. The commonly observed infectious diseases during Hajj include respiratory tract infections (influenza and pneumonia), urinary tract infections and skin infections that may necessitate the use of antimicrobials. Beta-lactams are used as a first-line treatment for hospital acquired infections as well as community acquired infections due to their broad-spectrum activity. However, most of the bacterial isolates such as Staphylococcus spp., Pseudomonas spp. and E. coli are resistant to beta-lactams. Irrational use of antimicrobials, lack of infection prevention practices and suboptimal healthcare access further exacerbate the risk of spreading AMR among Hajj pilgrims. Enhanced collaboration between countries, sharing of best practices and international cooperation are crucial in addressing AMR threats among pilgrims. Consequently, robust surveillance systems for early detection and monitoring of AMR, collaboration with national as well as international healthcare agencies, effective infection prevention and control measures, public awareness and rational use of antimicrobials via antimicrobial stewardship programs are required to mitigate the risk of AMR and ensure the health and well-being of pilgrims during Hajj.
- Open Access
- 29 June 2023
- Published by MDPI AG in Microbiology Research
- Vol. 14 (3) , 819-830
Comparative Assessment of Antimicrobial Efficacy of Seven Surface Disinfectants against Eight Bacterial Strains in Saudi Arabia: An In Vitro Study
Environmental conditions in hospitals facilitate the growth and spread of pathogenic bacteria on surfaces such as floors, bed rails, air ventilation units, and mobile elements. These pathogens may be eliminated with proper disinfecting processes, including the use of appropriate surface disinfectants. In this study, we aimed to evaluate of the antibacterial effects of seven surface disinfectants (HAMAYA, DAC, AJAX, Jif, Mr. MUSCLE, CLOROX, and BACTIL) against eight bacterial strains Klebsiella pneumoniae, Enterobacter aerogenes, Acinetobacter baumannii, Serratia marcescens, Escherichia coli, vancomycin-resistant Enterococcus faecalis-ATCC 51299, methicillin-resistant Staphylococcus aureus-ATCC 43300, and Pseudomonas aeruginosa-ATCC 1544, using two methods. The first was to determine the effective contact time of disinfectant against the tested bacterial strains, and the second was an assessment of the disinfection efficacy of each disinfectant on six types of contaminated surfaces with on a mixture of the eight tested bacterial strains. The results showed the efficacy of the disinfectants against the tested strains depending on the effective contact time. BACTIL disinfectant showed an efficacy of 100% against all tested strains at the end of the first minute of contact time. HAMAYA, DAC, Jif, Mr. MUSCLE, and CLOROX showed 100% efficiency at the end of the fourth, fifth, sixth, seventh, and fourteenth minutes, respectively, while AJAX disinfectant required nineteen minutes of contact time to show 100% efficacy against all tested strains.
- 29 June 2023
- Published by MDPI AG in Microbiology Research
- Vol. 14 (3) , 819-830
Open AccessComparative Assessment of Antimicrobial Efficacy of Seven Surface Disinfectants against Eight Bacterial Strains in Saudi Arabia: An In Vitro Study
Environmental conditions in hospitals facilitate the growth and spread of pathogenic bacteria on surfaces such as floors, bed rails, air ventilation units, and mobile elements. These pathogens may be eliminated with proper disinfecting processes, including the use of appropriate surface disinfectants. In this study, we aimed to evaluate of the antibacterial effects of seven surface disinfectants (HAMAYA, DAC, AJAX, Jif, Mr. MUSCLE, CLOROX, and BACTIL) against eight bacterial strains Klebsiella pneumoniae, Enterobacter aerogenes, Acinetobacter baumannii, Serratia marcescens, Escherichia coli, vancomycin-resistant Enterococcus faecalis-ATCC 51299, methicillin-resistant Staphylococcus aureus-ATCC 43300, and Pseudomonas aeruginosa-ATCC 1544, using two methods. The first was to determine the effective contact time of disinfectant against the tested bacterial strains, and the second was an assessment of the disinfection efficacy of each disinfectant on six types of contaminated surfaces with on a mixture of the eight tested bacterial strains. The results showed the efficacy of the disinfectants against the tested strains depending on the effective contact time. BACTIL disinfectant showed an efficacy of 100% against all tested strains at the end of the first minute of contact time. HAMAYA, DAC, Jif, Mr. MUSCLE, and CLOROX showed 100% efficiency at the end of the fourth, fifth, sixth, seventh, and fourteenth minutes, respectively, while AJAX disinfectant required nineteen minutes of contact time to show 100% efficacy against all tested strains.
- Open Access
- 12 January 2023
- Published by MDPI AG in Antibiotics
- Vol. 12 (1) , 164
Prevalence and Antibiogram Pattern of Klebsiella pneumoniae in a Tertiary Care Hospital in Makkah, Saudi Arabia: An 11-Year Experience
Infectious disease is one of the greatest causes of morbidity and mortality worldwide, and with the emergence of antimicrobial resistance, the situation is worsening. In order to prevent this crisis, antimicrobial resistance needs to be monitored carefully to control the spread of multidrug-resistant bacteria. Therefore, in this study, we aimed to determine the prevalence of infection caused by Klebsiella pneumoniae and investigate the antimicrobial profile pattern of K. pneumoniae in the last eleven years. This retrospective study was conducted in a tertiary hospital in Makkah, Saudi Arabia. Data were collected from January 2011 to December 2021. From 2011 to 2021, a total of 61,027 bacterial isolates were collected from clinical samples, among which 14.7% (n = 9014) were K. pneumoniae. The antibiotic susceptibility pattern of K. pneumoniae revealed a significant increase in the resistance rate in most tested antibiotics during the study period. A marked jump in the resistance rate was seen in amoxicillin/clavulanate and piperacillin/tazobactam, from 33.6% and 13.6% in 2011 to 71.4% and 84.9% in 2021, respectively. Ceftazidime, cefotaxime, and cefepime resistance rates increased from 29.9%, 26.2%, and 53.9%, respectively, in 2011 to become 84.9%, 85.1%, and 85.8% in 2021. Moreover, a significant increase in the resistance rate was seen in both imipenem and amikacin, with an average resistance rate rise from 6.6% for imipenem and 11.9% for amikacin in 2011 to 59.9% and 62.2% in 2021, respectively. The present study showed that the prevalence and drug resistance of K. pneumoniae increased over the study period. Thus, preventing hospital-acquired infection and the reasonable use of antibiotics must be implemented to control and reduce antimicrobial resistance.
- 12 January 2023
- Published by MDPI AG in Antibiotics
- Vol. 12 (1) , 164
Open AccessPrevalence and Antibiogram Pattern of Klebsiella pneumoniae in a Tertiary Care Hospital in Makkah, Saudi Arabia: An 11-Year Experience
Infectious disease is one of the greatest causes of morbidity and mortality worldwide, and with the emergence of antimicrobial resistance, the situation is worsening. In order to prevent this crisis, antimicrobial resistance needs to be monitored carefully to control the spread of multidrug-resistant bacteria. Therefore, in this study, we aimed to determine the prevalence of infection caused by Klebsiella pneumoniae and investigate the antimicrobial profile pattern of K. pneumoniae in the last eleven years. This retrospective study was conducted in a tertiary hospital in Makkah, Saudi Arabia. Data were collected from January 2011 to December 2021. From 2011 to 2021, a total of 61,027 bacterial isolates were collected from clinical samples, among which 14.7% (n = 9014) were K. pneumoniae. The antibiotic susceptibility pattern of K. pneumoniae revealed a significant increase in the resistance rate in most tested antibiotics during the study period. A marked jump in the resistance rate was seen in amoxicillin/clavulanate and piperacillin/tazobactam, from 33.6% and 13.6% in 2011 to 71.4% and 84.9% in 2021, respectively. Ceftazidime, cefotaxime, and cefepime resistance rates increased from 29.9%, 26.2%, and 53.9%, respectively, in 2011 to become 84.9%, 85.1%, and 85.8% in 2021. Moreover, a significant increase in the resistance rate was seen in both imipenem and amikacin, with an average resistance rate rise from 6.6% for imipenem and 11.9% for amikacin in 2011 to 59.9% and 62.2% in 2021, respectively. The present study showed that the prevalence and drug resistance of K. pneumoniae increased over the study period. Thus, preventing hospital-acquired infection and the reasonable use of antibiotics must be implemented to control and reduce antimicrobial resistance.